Drug intelligence / Profile preview

Adderall XR + mixed amphetamine salts immediate release

Development stage
Unknown
Lead developer
Takeda
Modality
Small Molecules
Administration
Oral
01

Overview

Adderall XR + mixed amphetamine salts immediate release is a combination therapy involving both the extended-release (XR) and immediate-release (IR) formulations of mixed amphetamine salts. Both formulations contain four different amphetamine salt forms—dextroamphetamine saccharate, dextroamphetamine sulfate, amphetamine aspartate monohydrate (racemic), and amphetamine sulfate (racemic)—in a 3:1 ratio of dextroamphetamine to levoamphetamine. The IR formulation provides rapid onset and short duration of action (4–6 hours), while the XR formulation uses a dual-bead delivery system for biphasic release over up to 12 hours. This combination is sometimes used clinically to provide both sustained symptom control throughout the day and flexibility for acute symptom management in attention deficit hyperactivity disorder (ADHD) or narcolepsy. Mechanistically, these drugs act as central nervous system stimulants by increasing synaptic concentrations of dopamine and norepinephrine through promoting their release from presynaptic neurons[1][2][3][5][8].

Brand names
Adderall
Other names
mixed amphetamine salts extended-releasemixed amphetamine salts immediate-releaseMAS-ERMAS-IR
02

Targets

SERT (Sodium-dependent serotonin transporter)TAAR1 (Trace amine-associated receptor 1)DAT (Dopamine plasma membrane transport protein)VMAT2 (Vesicular monoamine transporter 2)MAOA (Monoamine oxidase A)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on Adderall XR + mixed amphetamine salts immediate release.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adderall XR + mixed amphetamine salts immediate release.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call